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Abstract  1 
 Biological macromolecular drugs, such as antibodies and fusion protein drugs, have been 2 
widely employed for the treatment of various diseases. Administration routes are typically via 3 
invasive intravenous or subcutaneous injection with needles; the latter is challenging for applications 4 
involving inflamed skin (e.g., psoriasis) due to concerns of expansion of inflammation. As a method 5 
of non-invasive transdermal drug delivery, we previously demonstrated that iontophoresis (IP) using 6 
weak electric current (0.3-0.5 mA/cm2) enables transdermal permeation of hydrophilic 7 
macromolecules, such as small interfering RNA and nanoparticles into the skin, and subsequent 8 
exertion of their functions. The underlying mechanism was revealed to be via intercellular junction 9 
cleavage by cellular signaling activation initiated by Ca2+ influx. Based on these findings, in the 10 
present study, we hypothesized that non-invasive intradermal delivery of biological macromolecular 11 
drugs could be efficiently achieved via IP. Fluorescence of FITC-labeled IgG antibody was broadly 12 
observed in the skin after IP administration (0.4 mA/cm2 for 1 h) and extended from the epidermis to 13 
the dermis layer of hairless rats; passive antibody diffusion was not observed. In imiquimod-induced 14 
psoriasis model rats, antibodies were also delivered via IP into inflamed skin tissue. Additionally, 15 
upregulation of interleukin-6 mRNA levels, which is related to pathological progression of psoriasis, 16 
was significantly inhibited by IP of the anti-tumor necrosis factor-α drug etanercept, but not by its 17 
subcutaneous injection. Importantly, IP administration of etanercept significantly ameliorated 18 
epidermis hyperplasia, a symptom of psoriasis. Taken together, the present study is the first to 19 
demonstrate that IP can be applied as a non-invasive and efficient intradermal drug delivery 20 
technology for biological macromolecular drugs. 21 
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Keywords 23 
Iontophoresis; Transdermal drug delivery; Biological macromolecular drugs; Antibody; Psoriasis; 24 




1. Introduction 1 
 In recent years, biological macromolecular drugs, such as antibodies and fusion protein 2 
drugs, have been developed and employed for the treatment of various diseases, including cancer and 3 
inflammatory diseases [1-3]. A therapeutic advantage of biological macromolecular drugs in 4 
comparison to conventional low molecular weight drugs is that the former can exert high therapeutic 5 
benefit with fewer side effects by selectively binding to or capturing their target molecules. Most 6 
administration routes for biological macromolecular drugs have been via systemic delivery by 7 
intravenous or subcutaneous injection with needles. While injection is generally recognized as an 8 
instantaneous and effective administration method, there are several problems with injection methods, 9 
such as invasiveness, pain, and risk of infection due to repeated use of a needle, which leads to 10 
concerns of decreased patient compliance [4-6]. Also, skilled techniques are often required for secure 11 
injection.  12 
 Psoriasis is an autoimmune disease that follows chronic courses with inflammatory 13 
symptoms of the skin, and is typically treated using biological macromolecular drugs [7, 8]. 14 
Although the specific causes of the disease have not yet been elucidated, it has been reported that 15 
excess production of inflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-8, tumor necrosis 16 
factor (TNF)-α, and interferon-γ, around the diseased site is involved in pathological progression of 17 
psoriasis [8]. Among these inflammatory cytokines, TNF-α has been demonstrated to be an important 18 
therapeutic target in psoriasis, and various biological macromolecular drugs, including antibody 19 
agents such as infliximab, adalimumab, and the anti-TNF-α drug etanercept, represent effective 20 
therapeutic agents for psoriasis [9, 10]. Most of these agents are administered by injection, 21 
specifically subcutaneous (s.c.) injection. However, administration of these agents to abnormal skin, 22 
including psoriatic eruption, is often avoided due to the risk of inflammatory expansion, thus limiting 23 
the site where s.c. injection can be performed. In addition, the administration site must be changed 24 
for each subsequent injection. Moreover, needle insertion for s.c. injection often results in vascular 25 
inflammation, and is associated with a risk of adverse skin effects (e.g., redness and rash) at the 26 
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injection site [11]. Hence, development of a new method capable of non-invasive and efficient 1 
delivery of biological macromolecular drugs into psoriatic inflamed skin is needed to mitigate the 2 
above-mentioned problems. 3 
 To increase transdermal drug delivery efficiency, several physical technologies including 4 
iontophoresis (IP) [12, 13], electroporation [14], sonophoresis [15], and microneedles [16], have 5 
been reported. Among these technologies, we have focused on IP using weak electric current (0.3-0.5 6 
mA/cm2), which offers a simple and non-invasive method compared with other methods, as needles 7 
and other complicated devices are not required. IP can be used to promote transdermal permeation of 8 
charged molecules into skin tissue. However, IP has typically been considered to be applicable only 9 
for charged low molecular weight compounds with relatively high hydrophobicity via 10 
electrorepulsion and electroosmosis [17]. We recently succeeded in the intradermal delivery of 11 
hydrophilic macromolecular drugs, including small interfering RNA (siRNA; M.W. ca. 12,000) and 12 
CpG oligo DNA (M.W. ca. 6,600) via IP, and demonstrated successful exertion of their functions in 13 
vivo (i.e., RNA interference and immune-activation, respectively) [18, 19]. In our previous studies, 14 
we also reported that nanoparticles, such as insulin-encapsulating liposomes and antigen 15 
peptide-loaded nanogels, can also be intradermally delivered via IP [20, 21]. The mechanism of 16 
IP-mediated permeation of hydrophilic macromolecules and nanoparticles into skin tissues was 17 
previously revealed to involve Ca2+-mediated intracellular signal activation induced in skin cells by 18 
IP, followed by decreased expression of gap-junction protein Cx43 and depolymerization of 19 
polymerized actin, a tight junction associated protein, resulting in intercellular junction cleavage [22]. 20 
An advantage of IP-mediated drug delivery is that intradermally delivered drugs via IP are gradually 21 
released into the systemic circulation while maintaining a certain concentration in the blood upon 22 
sustained movement from the skin tissue to the circulation, by the skin acting as a reservoir [12]. 23 
Based on these findings, we hypothesized that IP could offer a non-invasive, safe, and efficient 24 
transdermal technology for delivery of biological macromolecular drugs, such as antibodies and 25 
fusion protein drugs, which typically exhibit very high molecular weights (ca. ≥150,000). Moreover, 26 
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IP may be able to be applied for the treatment of psoriasis as an alternative to invasive s.c. injection. 1 
 In the present study, we examined the transdermal delivery into skin tissue via IP of an 2 
antibody as a representative biological macromolecular drug. We employed a previously reported 3 
psoriasis rat model [23, 24] to investigate whether the antibody can also be delivered into the 4 
psoriatic inflamed skin tissue by IP. Finally, we evaluated the functionality of the anti-TNF-α drug 5 
etanercept (recombinant human TNF-α receptor: Fc fusion protein), delivered via IP into the skin of 6 
the psoriasis model rats. We compared the effectiveness of IP-mediated etanercept administration 7 





2. Methods 1 
 2 
2.1. Animals 3 
 Male HWY hairless rats (190-210 g) were purchased from Japan SLC, Inc. (Shizuoka, 4 
Japan) and were 7 weeks old at the beginning of each experiment. All animal experiments were 5 
evaluated and approved by the Animal and Ethics Review Committee of Tokushima University. 6 
 7 
2.2. Iontophoresis (IP) of fluorescent-labeled antibody 8 
 IP of antibodies was performed in accordance with our previous reports [22]. Briefly, 9 
normal HWY hairless rats were anesthetized by intraperitoneal injection of chloral hydrate (400 10 
mg/kg rat) dissolved in phosphate-buffered saline (PBS). To administer fluorescein isothiocyanate 11 
(FITC)-labeled IgG antibody (Sigma-Aldrich, Tokyo, Japan), nonwoven fabric (2.25 cm2) containing 12 
1 mg (200 µL) of FITC-labeled IgG solution (5 mg/mL) was placed on the dorsal skin, and a 13 
nonwoven fabric moistened with 200 µL of PBS was also placed 1 cm away. Each piece of 14 
nonwoven fabric containing IgG and PBS was attached to Ag-AgCl electrodes (3M Health Care, 15 
Minneapolis, MN, USA) with surface areas of 2.25 cm2. The Ag-AgCl electrodes with nonwoven 16 
fabric containing FITC-labeled IgG or PBS were connected to the cathode and anode, respectively, 17 
of a power supply (TTI ellebeau, Inc., model TCCR-3005, Tokyo, Japan). After covering the 18 
connections with tape, IP was performed with a constant current of 0.4 mA/cm2 (0.9 mA) for 1 h. 19 
 20 
2.3. Intradermal distribution of fluorescent-labeled antibody after IP 21 
 At 0 or 3 h after 1-h IP of FITC-labeled IgG as described above, the skin of the rats was 22 
removed, embedded in optimal cutting temperature (OCT) compound (Sakura Finetek, Tokyo, Japan), 23 
and then frozen with dry ice/ethanol. The frozen skin sections were cut into 10-µm thick sections 24 
using a cryostat (CM3050S; Leica Biosystems, Tokyo, Japan). The 10-µm thick frozen sections were 25 
mounted onto MAS-coated slide glasses with Perma Fluor Aqueous Mounting Medium (Thermo 26 
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Fisher Scientific, Waltham, MA, USA). FITC fluorescence of the skin sections was observed with a 1 
confocal laser scanning microscope (LSM700, Carl Zeiss, Jena, Germany). 2 
 3 
2.4. Immunostaining of intercellular junction proteins 4 
 The 10-µm thick frozen skin sections were immunostained for a gap junction protein 5 
connexin 43 (Cx43), an intercellular junction protein. Briefly, the sections were fixed with 4% 6 
paraformaldehyde (PFA) for 15 min at room temperature, and incubated with 1% bovine serum 7 
albumin (BSA) in PBS for 20 min at room temperature. Then, the sections were incubated with 8 
rabbit anti-Cx43 antibody (ab11370, Abcam, Cambridge, UK) at a dilution of 1:100 at 4ºC overnight. 9 
Next, the sections were incubated with Alexa 647-conjugated goat anti-rabbit IgG antibody 10 
(ab150079; Abcam) at a dilution of 1:200 for 60 min at 37ºC. After mounting with Perma Fluor 11 
Aqueous Mounting Medium, the fluorescence in the sections was observed by confocal laser 12 
scanning microscopy. 13 
 14 
2.5. Preparation of psoriasis model rats 15 
 Psoriasis model rats were prepared as previously reported [23]. Briefly, 7-week-old hairless 16 
rats were anesthetized with 3% isoflurane (Escain®, Pfizer, NY, USA) and maintained with 1.5% 17 
isoflurane. Under isoflurane anesthesia, 60 mg of imiquimod (IMQ) cream (5%; Beselna cream; 18 
Mochida Pharmaceuticals, Tokyo, Japan) was topically applied onto the dorsal skin of rats, after 19 
which the rats were allowed to recover from anesthesia. IMQ treatment was performed 4 times per 20 
24 h to induce psoriasis, and the resultant rats were used in the following experiments.  21 
 22 
2.6. Hematoxylin-eosin (HE) staining of inflamed skin of the psoriasis model 23 
 To confirm induction of psoriasis, the skin of the rats treated with IMQ cream for 4 days 24 
was removed at day 8 after the start of IMQ treatment (day 1), and the frozen skin sections (10 µm) 25 
were prepared as described above. The sections were then fixed with 4% PFA for 10 min. After 26 
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washing with PBS, the sections were stained with Mayer’s hematoxylin solution (Fuji Film Wako 1 
Pure Chemical, Osaka, Japan) for 10 min at room temperature, and subsequently with 1% eosin (Fuji 2 
Film Wako Pure Chemical) for 1 min at room temperature. The samples were then dehydrated with 3 
80-100% ethanol, cleared with xylene, and mounted with hydrophobic mounting medium 4 
(Entellan®New, Merck Millipore, Burlington, MA, USA). Finally, the sections were observed using a 5 
fluorescence phase contrast microscope (BZ-9000, Keyence, Osaka, Japan).  6 
 7 
2.7. Intradermal distribution of IP-delivered FITC-labeled antibody in psoriatic skin 8 
 At 24 or 72 h after the 4th IMQ treatment on the dorsal skin of hairless rats, IP 9 
administration of FITC-labeled IgG was carried out as described above (2.2. Iontophoresis (IP) of 10 
fluorescent-labeled antibody). Three hours after each treatment with FITC-labeled IgG, 10-µm frozen 11 
sections of the psoriatic inflamed skin were prepared. Following the addition of 12 
4’,6-diamidino-2-phenylindole (DAPI) solution (1.0 µg/mL, Thermo Fisher Scientific) onto the 13 
sections, the sections were then mounted with Perma Fluor Aqueous Mounting Medium. The 14 
fluorescence of FITC and DAPI in the skin sections was observed by confocal laser scanning 15 
microscopy.  16 
 17 
2.8. IP of biological macromolecular drugs onto the psoriasis model 18 
 IMQ cream-induced psoriasis model rats were anesthetized with chloral hydrate (400 mg/kg 19 
rat). Nonwoven fabric (2.25 cm2) containing 1 mg (200 µL) of a solution of the anti-TNF-α drug 20 
etanercept (recombinant human soluble TNF-α receptor: Fc fusion protein) was attached to Ag-AgCl 21 
electrodes with surface area of 2.25 cm2, and applied onto the skin to induce psoriatic inflammation. 22 
The Ag-AgCl electrodes with nonwoven fabric containing etanercept or PBS were connected to the 23 
cathode and anode of a power supply, respectively. After covering the connections with tape, IP was 24 
performed with a constant current of 0.4 mA/cm2 (0.9 mA) for 1 h. The iontophoretic administration 25 
of etanercept was performed 24 and 72 h after the 4th IMQ treatment on the dorsal skin of hairless 26 
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rats. Twenty-four hours after the 2nd IP treatment, the skin under the cathode was removed and total 1 
RNA was isolated as described in the following section to evaluate the function of IP-delivered 2 
etanercept.  3 
 4 
2.9. RNA extraction 5 
 The skin of each IMQ-induced psoriasis model rat in each group was removed and 6 
immersed in Allprotect Tissue Reagent (QIAGEN, Hilden, Germany) to stabilize RNA before 7 
extraction. Next, 250 mg of the cut skin tissue was homogenized in 5 mL of QIAzol Lysis reagent 8 
(QIAGEN) using a TissueRuptor II (QIAGEN). After 5 min of incubation at room temperature, total 9 
RNA was purified and extracted with an RNeasy Plus Universal Midi kit (QIAGEN) according to the 10 
manufacturer’s instructions. The total RNA concentration was quantified using a Nanodrop 8000 11 
(Thermo Fisher Scientific). 12 
 13 
2.10. Quantitative analysis of mRNA expression of inflammatory cytokines by real-time reverse 14 
transcription polymerase chain reaction (RT-PCR)  15 
 cDNA was synthesized from 200 ng of total RNA with PrimeScript RT Master Mix (Perfect 16 
Real Time, Takara Bio, Otsu, Japan) and an MJ Mini Personal Thermal Cycler (Bio-Rad, Hercules, 17 
CA, USA). The conditions for the reverse transcription reaction were 37℃ for 15 min, whereas those 18 
for inactivation of reverse transcriptase were 85ºC for 5 sec. Real-time RT-PCR analysis was 19 
performed using TB GreenTM Premix Ex TaqTM II (Tli RNaseH Plus, Takara Bio) and a Thermal 20 
Cycler Dice Real Time System III (Takara Bio). To analyze the mRNA expression levels of TNF-α, 21 
IL-6, and GAPDH, the cDNA was denaturated at 95ºC for 30 sec, followed by 40 cycles of 95ºC for 22 
5 sec and 60ºC for 30 sec for amplification. The sequences of the primers used for the real-time 23 
RT-PCR are shown in Table 1. The mRNA levels of TNF-α and IL-6 were calculated using the 2-ΔΔCt 24 
method by normalization relative to GAPDH mRNA. The relative transcript levels (TNF-α/GAPDH 25 




2.11. Evaluation of epidermis thickness 2 
 HE staining was performed for the 10-µm frozen skin tissues of psoriasis model rats in each 3 
treatment group, as described above (2.6. Hematoxylin-eosin (HE) staining of inflamed skin of the 4 
psoriasis model). Then, the sections were observed with a fluorescence phase contrast microscope 5 
(BZ-9000), and average epidermis thickness was calculated from over 20 images per rat by using an 6 
image analysis application of BZ-9000. 7 
 8 
2.12. Statistical analysis 9 
 Statistical differences were evaluated by one-way analysis of variance with the Tukey 10 
post-hoc test. Comparison between two groups were determined using the Student’s t-test. Data are 11 
presented as mean ± standard deviation (S.D.). 12 
 13 
 14 
Table 1. Primer sequences for real-time RT-PCR. 15 
   
Gene Forward Reverse 
GAPDH CCCCCAATGTATCCGTTGTG TAGCCCAGGATGCCCTTTAGT 
TNF-α CGTAGCAAACCACCAAGCA CGTAGCAAACCACCAAGCA 
IL-6 TCCTACCCCAACTTCCAATGCTC TTGGATGGTCTTGGTCCTTAGCC 





3. Results  1 
 2 
3.1. Intradermal distribution of FITC-labeled IgG delivered via iontophoresis 3 
 We performed transdermal delivery of FITC-labeled IgG (M.W. ca. 150,000) via IP on the 4 
dorsal skin of hairless rats. Fluorescence was hardly observed in the skin tissues at 3 h after treatment 5 
for both topical skin application of FITC-IgG alone onto the skin (i.e., passive diffusion) and 6 
iontophoretic treatment alone (Figs. 1A and B). On the other hand, when FITC-IgG solution was 7 
administered via IP, fluorescence was clearly observed around the epidermis immediately after 1-h IP 8 
(Fig. 1C), as judged from the image of the HE-stained skin in Fig. 1F. Surprisingly, broad 9 
fluorescence of the antibody was observed extending from the epidermis layer to the dermis layer at 10 
3 h after IP-mediated delivery of the antibody (Figs. 1D and E). In addition, to quantify the amount 11 
of FITC-IgG administered via IP, we harvested the nonwoven fabric, in which FITC-IgG was 12 
impregnated, attached onto cathodal Ag-AgCl electrode immediately after 1-h IP, and immersed in 1 13 
mL PBS to extract FITC-IgG retained in the nonwoven fabric. Then, the FITC fluorescence in extract 14 
was measured. The results showed that the retained FITC-IgG in nonwoven fabric after IP was 16.4 15 
± 1.1% (n=3) of applied FITC-IgG, suggesting that approximately 80% of the FITC-IgG could be 16 
administered by IP. These results suggest that antibodies, which are very large molecules with high 17 





Fig. 1. Intradermal distribution of fluorescent-labeled antibody delivered by iontophoresis (IP). 2 
 Confocal images of 10-µm frozen skin sections of hairless rats applied with FITC-IgG 3 
without IP (0.4 mA/cm2) for 3 h (A; n=3) and 3 h after treatment by 1-h IP alone (B; n=3). The 4 
hairless rats were also transdermally administered FITC-IgG via 1-h IP. At 0 h (C; n=4) and 3 h (D 5 
and E; n=4) after 1-h IP, FITC fluorescence was observed by confocal microscopy. Scale bars = 100 6 
µm. Image of dorsal skin tissue of hairless rats stained with HE (F). Stratum corneum, epidermis, and 7 
dermis. Scale bar = 100 µm.  8 
 9 
 We next performed immunostaining for an intercellular gap junction protein, connexin 43 10 
(Cx43), to confirm the induction of intercellular junction cleavage via IP and to observe the 11 
relationship between intradermal distribution of FITC-IgG delivered by IP and Cx43 expression. The 12 
13 
 
confocal images showed that the expression of Cx43 was widely observed in the skin tissue not 1 
treated by IP (Fig. 2A). IP treatment induced obvious reduction of Cx43 expression (Fig. 2B), similar 2 
to our previous report [22]. Importantly, the fluorescence of FITC-IgG was remarkably observed in 3 
the region where the Cx43 expression decreased around both the epidermis and dermis layers (Fig. 4 
2C). These results suggest that FITC-IgG could be permeated into skin tissue by IP through the 5 
cellular gap derived from cleaved intercellular junction by IP treatment.  6 
Fig. 2. Transdermal permeation of fluorescence-labeled antibody via the cleaved intercellular 7 
junctions induced by IP. 8 
 The rats were transdermally administered FITC-IgG via 1-h IP. Three hours after 1-h IP, the 9 
skins of the rats were dissected, and 10-µm frozen sections were prepared, followed by 10 
immunostaining for an intercellular gap junction protein Cx43. The fluorescence images of the skin 11 
were obtained by confocal laser scanning microscopy. The images of the skin sections (A; IP (-)), (B; 12 
IP (+)/FITC-IgG (-), (C) IP (+)/FITC-IgG (+)) are shown. (C) The images in left column indicate the 13 
images obtained around the epidermis and those in right column around the dermis. Green and red 14 
indicate FITC (IgG) and Alexa647 (Cx43), respectively. Merged images of FITC, Alexa647, and 15 





3.2. Preparation of IMQ-induced psoriasis model and IP-mediated delivery of antibodies into 1 
psoriatic skin 2 
 Following the successful transdermal delivery of biological macromolecular drugs by IP, we 3 
examined whether this macromolecular delivery technology can be employed for therapeutic 4 
application against an inflammatory disease, namely psoriasis, which is typically treated with 5 
biological macromolecular drugs. Following repeated treatment of the dorsal skin with IMQ for a 6 
total of 4 times, induction of psoriatic inflammation was histologically examined by HE staining. As 7 
shown in the images of HE-stained skin in Figs. 3A and B, hyperplasia of the epidermis was clearly 8 
observed for IMQ-induced psoriasis compared with non-treated normal rats, suggesting that the 9 
psoriasis model was successfully prepared in accordance with previous reports [23, 24].  10 
 11 
Fig. 3. Evaluation of psoriatic skin inflammation in IMQ-induced psoriasis model rats. 12 
The psoriasis model rats were prepared by topical application of IMQ cream (60 13 
mg/rat/treatment) a total of four times. Eight days after the 1st IMQ treatment (day 1), 10-µm frozen 14 
skin sections were prepared, and HE staining was performed. Microscopic images of skin sections 15 




Using this psoriasis model, we investigated the intradermal distribution of FITC-IgG 1 
administered by IP. As shown in Fig. 4A, topical skin application of FITC-IgG alone (passive 2 
diffusion), IP alone, and IP of FITC-IgG was performed 24 h after the 4th IMQ treatment, whereas IP 3 
of FITC-IgG was conducted twice in the other group of rats at 24 and 72 h after the last IMQ 4 
treatment. Confocal images, which were obtained from skin sections prepared 3 h after each 5 
treatment, showed no FITC fluorescence in the groups with topical skin application of FITC-IgG or 6 
IP alone (Figs. 4B and C). Further, the fluorescence derived from FITC-IgG was prominently 7 
detected by IP-mediated administration of the antibody (Fig. 4D). In an effort to deliver the antibody 8 
more reliably, two doses of the antibody IP were carried out and the subsequent intradermal 9 
distribution was observed. Similar to the results obtained using the single dose, FITC fluorescence 10 
was strongly detected in the psoriatic skin (Fig. 4E). Taken together, these results suggest that IP can 11 
be applied for intradermal delivery of biological macromolecular drugs, such as antibodies, even in 12 





Fig. 4. Iontophoretic delivery of fluorescent-labeled antibody into the dorsal skin of IMQ-induced 2 
psoriasis model rats. 3 
 Experimental schedule (A). Twenty-four hours (day 5) after the 4th IMQ treatment (day 4), 4 
the rats were treated with FITC-IgG alone (B; n=3), IP alone (C; n=3), or IP administration of 5 
FITC-IgG (D; n=3), followed by preparation of 10-µm frozen skin sections 3 h after treatment. In 6 
those rats administered FITC-IgG by IP twice (E; n=3, day 5 and 7), the sections were prepared 3 h 7 
after the 2nd treatment. Confocal images of each group are shown (B; IP (-)/FITC-IgG (+), C; IP 8 
(+)/FITC-IgG (-), D; IP (+)/FITC-IgG (+) 1 time, E; IP (+)/FITC-IgG (+) 2 times). Merged images of 9 




3.3. Iontophoretic delivery of etanercept 1 
 Next, we examined the biological function of a macromolecular drug delivered into the 2 
psoriatic skin via IP. The anti-TNF-α drug etanercept was chosen as a representative therapeutic 3 
biological macromolecular drug in this study. Since there are a lot of reports about the usefulness of 4 
etanercept on several inflammatory diseases such as psoriasis in mice [25], arthritis [26, 27], and 5 
traumatic brain injury in rats [28], cross reactivity of etanercept between human and rats has been 6 
demonstrated. IP treatments (0.4 mA/cm2, 1 h) of etanercept were performed on the psoriatic 7 
inflamed skin at 24 and 72 h after the last IMQ treatment, followed by assessment of mRNA levels of 8 
inflammatory cytokines (TNF-α and IL-6), as shown in Fig. 5A. The results showed that mRNA 9 
levels of TNF-α and IL-6 were significantly increased in IMQ-treated psoriasis model rats compared 10 
with normal rats (IMQ (-)) (Figs. 5B and C). As several inflammatory cytokines have been reported 11 
to induce hyperplasia of the epidermis, these results provide support for the HE staining image of the 12 
psoriatic dorsal skin shown in Figure 3. Transdermal administration of etanercept via IP had no effect 13 
on TNF-α mRNA levels in comparison with non-treated and PBS (IP) groups (Fig. 5D). On the other 14 
hand, IL-6 mRNA levels were significantly reduced by IP delivery of etanercept compared with 15 
non-treated and PBS (IP)-treated groups (Fig. 5E). By performing Western blotting, we also 16 
evaluated TNF-α protein expression in psoriatic skin and effect of IP-mediated delivered etanercept 17 
on its expression. The results showed that IMQ treatment markedly increased TNF-α protein 18 
expression compared with normal rat (Supplementary Fig. 1A). The levels of TNF-α protein 19 
expression was significantly decreased by etanercept administration via IP compared with 20 
IMQ-treated rats (Supplementary Fig. 1A and B), although decrease of the expression was only 14% 21 
at day 8 of the present therapeutic regimen. It is previously reported that TNF-α induces upregulation 22 
of IL-6 mRNA via NF-κB phosphorylation in skin cells under inflammatory conditions [29, 30]. 23 
Based on these reports and our present results, it is suggested that etanercept exerts its function upon 24 
delivery into psoriatic skin via IP and captures TNF-α, resulting in possible suppression of 25 
downstream signaling and decrease of upregulated IL-6 mRNA; although upregulation of TNF-α 26 
18 
 
mRNA could not be inhibited by etanercept. 1 
Fig. 5. Effects of IP-mediated etanercept treatment on inflammatory cytokine mRNA levels in 2 
psoriasis model rats. 3 
 IMQ-treated psoriasis model rats were transdermally administered etanercept (1 mg 4 
dose/rat) or PBS via IP 5 and 7 days after the start of IMQ treatment (A). Eight days after the start of 5 
IMQ treatment, the mRNA levels of TNF-α (B) and IL-6 (C) were assessed. The relative transcript 6 
levels of TNF-α and IL-6 in IMQ (+) to those in the IMQ (-) non-treated group are presented. In the 7 
IP-treated group, the mRNA levels of TNF-α (D) and IL-6 (E) were assessed at 24 h after the 2nd IP 8 
treatment. The relative transcript levels in each group to those in the IMQ (+) non-treated group are 9 




3.4. Effect of subcutaneous injection of etanercept into psoriasis model rats 1 
 Following the successful demonstration that biological macromolecular drugs can be 2 
delivered into skin tissue by IP and exert their native functions, we compared IP with a conventional 3 
administration route of etanercept for psoriasis treatment, namely s.c. injection. The experimental 4 
procedure for s.c. injection was similar to that of IP administration with the exception that etanercept 5 
and PBS were injected s.c. into the psoriasis model rats (Fig. 6A). In the s.c. PBS-treated group, 6 
TNF-α mRNA levels tended to increase, and a significant increase of IL-6 mRNA levels was induced 7 
(Fig. 6B and C), suggesting that needle insertion into psoriatic skin causes an inflammatory reaction. 8 
In contrast, in the groups receiving s.c. injection of etanercept into lesion or non-lesion sites, mRNA 9 
levels of TNF-α and IL-6 tended to be lower than those of PBS-treated groups, whereas levels were 10 
comparable to or higher than those of the IMQ (+) group (Figs. 6B and C). The results shown in Figs. 11 
5 and 6 demonstrate that IP can more effectively deliver biological macromolecular drugs into 12 
inflamed skin without induction of an inflammatory reaction as induced by conventional s.c. 13 
injection with needle. In addition, as shown in the images of HE staining in Supplementary Fig. 2, s.c. 14 
needle insertion caused scars of needle penetration from epidermis to dermis layers both in normal 15 
and psoriatic skins. On the other hand, IP treatment hardly caused such scars and obvious damage 16 
including epidermis hyperplasia by inflammation in the skin tissues, suggesting that IP is 17 





Fig. 6. Effects of subcutaneous (s.c.) injection of etanercept on inflammatory cytokine mRNA levels 1 
in the psoriasis model rats. 2 
 IMQ-treated psoriasis model rats were subcutaneously injected with etanercept (1 mg 3 
dose/rat) or PBS at 5 and 7 days after the start of IMQ treatment (A). In etanercept-treated groups, s.c. 4 
injections were performed directly into the psoriatic inflammatory skin (lesion site) or the distal area 5 
from the diseased site (non-lesion site), respectively. Twenty-four hours after the 2nd s.c. injection, 6 
the mRNA levels of TNF-α (B) and IL-6 (C) were evaluated. The relative transcript levels of TNF-α 7 




3.5. Therapeutic outcome of etanercept delivered via IP on psoriasis 1 
 Finally, we investigated therapeutic outcome of etanercept delivered via IP in psoriasis 2 
model rats by evaluating epidermis thickness as an indication of epidermis hyperplasia. The results 3 
of HE staining showed that the IMQ treatment significantly induced epidermis hyperplasia compared 4 
with non-treated normal hairless rats (Figs. 7A, B, and E), similar to the images of HE staining in Fig. 5 
3. IP administration of etanercept significantly ameliorated epidermis hyperplasia in comparison to 6 
IMQ-treated rats (Figs. 7C and E). Importantly, the therapeutic effect of IP-delivered etanercept was 7 
significantly higher than s.c. injected etanercept (Figs. 7C-E). These results suggest that etanercept 8 
delivered by IP effectively exerted its function and ameliorated the symptom of psoriasis in 9 
IMQ-treated model rats, and that IP should be useful as a non-invasive transdermal delivery 10 




Fig. 7. Amelioration of epidermis hyperplasia by etanercept delivered via IP in psoriasis model rats. 1 
 Etanercept (1 mg dose/rat) was transdermally (IP) or subcutaneously administered 5 and 7 2 
days after the start of IMQ treatment. Eight days after the start of IMQ treatment, the 10-µm frozen 3 
skin sections were prepared and stained with HE. Microscopic images of skin sections from normal 4 
(A; n=3), IMQ-treated psoriasis model rats (B; n=4), the model rats treated with etanercept 5 
administered by IP (C; n=4) or s.c. injection (D; n=4). Scale bars = 100 µm. From the images of 6 
HE-stained skin sections, epidermis thickness of each group of rats was measured (E). Data are mean 7 




4. Discussion 1 
 Our previous studies revealed that hydrophilic macromolecules, such as siRNA and CpG 2 
oligo DNA as well as nanoparticles including liposomes and nanogels, can be intradermally 3 
delivered into skin tissue by intercellular junction cleavage via IP using weak electric current (0.3-0.5 4 
mA/cm2) [18-21]. We also demonstrated that activation of protein kinase C-α and Ca2+ influx is 5 
involved in the intercellular junction cleavage via gap junction dissociation by Cx43 reduction and 6 
filamentous actin depolymerization [22]. Based on these findings, we sought to apply IP to the 7 
intradermal delivery of biological macromolecular drugs, including antibodies. As shown in Fig. 1, 8 
FITC-IgG permeated into the skin tissue around the epidermis immediately after 1-h IP (Fig. 1C), 9 
although passive diffusion was not observed. By quantification of the retained FITC-IgG in 10 
nonwoven fabric immediately after IP, it was revealed that approximately 80% of the FITC-IgG 11 
could be administered by IP, although the intradermal amount of FITC-IgG could not be detected. 12 
Broad FITC fluorescence of the antibody was observed both in and around the epidermis and dermis 13 
layers at 3 h after IP administration (Figs. 1D and E). In particular, the fluorescence of FITC-IgG was 14 
remarkably observed in the region where the expression of intercellular gap junction protein Cx43 15 
decreased via IP (Fig. 2). These results suggest that antibodies that exhibit higher molecular weights 16 
compared with functional nucleic acids, including siRNA, can also reach the dermis layer from the 17 
epidermis layer via the cleaved cellular gap due to IP.  18 
 We applied the IP delivery technology to the treatment of psoriasis. In IMQ-induced 19 
psoriasis model rats, FITC-IgG administered via IP was found to permeate into inflamed skin tissue 20 
(Figs. 4D and E). However, in the psoriasis model, the IP-delivered antibodies only reached shallow 21 
sites compared with normal skin tissue (Figs. 1C-E). It was previously reported that keratinocytes in 22 
the epidermis are highly proliferative in response to several inflammatory cytokines, including 23 
TNF-α and IL-6, in inflamed psoriatic skin [29, 31, 32]. Indeed, hyperplasia of epidermis was clearly 24 
observed in the dorsal skin of hairless rats after IMQ treatment in the present study (Fig. 3). The 25 
proliferating keratinocytes secrete various cytokines to migrate immune cells such as leukocytes and 26 
24 
 
T cells into the layers of epidermis and dermis [33]. Based on these findings, it is considered that the 1 
psoriatic skin forms cellular barriers due to the epidermis hyperplasia by over-proliferated 2 
keratinocytes and accumulated immune cells. Owing to the cellular barriers in the skin, the effect of 3 
intercellular junction cleavage via IP would not have reached the dermis layer of psoriatic skin, so 4 
that the FITC-IgG administered by IP could not penetrate so deeply into the psoriatic skin and might 5 
stay in the stratum corneum and epidermis layer in the confocal images (Fig. 4).  6 
 The function of intradermally-delivered biological macromolecular drugs was evaluated 7 
using the anti-TNF-α drug etanercept as a representative therapeutic agent. It was previously reported 8 
that under psoriatic conditions, TNF-α produced in the skin immune cells and keratinocytes binds to 9 
its receptors and activates the NF-κB signaling pathway, resulting in promotion of IL-6 production 10 
[29, 30, 32]. In the present study, IMQ treatment onto the dorsal skin of rats significantly induced 11 
upregulation of both TNF-α and IL-6 mRNA levels (Fig. 5). Only IP treatment had minimal effects 12 
on mRNA levels. IP administration of two doses of etanercept significantly reduced IL-6 mRNA 13 
levels by 50%, whereas levels of TNF-α mRNA were not reduced by etanercept IP. On the other hand, 14 
the expression of TNF-α protein in the psoriatic skins significantly decreased by IP-mediated 15 
delivery of etanercept (Supplementary Fig. 1), although decrease of the expression was only 14% at 16 
day 8 of the present therapeutic regimen. These results suggest that etnercept was efficiently 17 
delivered into psoriatic skin by IP and exerted its function, capturing TNF-α around the diseased sites, 18 
and possibly resulting in subsequent inhibition of downstream inflammatory signals.  19 
 Needle injection into inflamed skin can cause further progression of inflammation [11, 34]. 20 
In fact, in the present study, s.c. needle injection into the dorsal skin of IMQ-treated rats induced an 21 
increase in both TNF-α and IL-6 levels (Fig. 6). On the other hand, when etanercept was 22 
administered via s.c. injection, the mRNA levels of these inflammatory cytokines did not decrease 23 
compared with the IMQ-treated group, regardless of whether the injection was performed on lesion 24 
or non-lesion sites. However, s.c. injection of etanercept tended to decrease the levels compared with 25 
those of the PBS group. These results suggest that while s.c.-injected etanercept was able to exert its 26 
25 
 
effect, the effect was offset by the invasiveness of the needle injection. In fact, s.c. needle insertion 1 
caused scars of needle penetration from epidermis to dermis layers both in normal and psoriatic skins, 2 
whereas IP treatment hardly caused such scars and obvious damage including epidermis hyperplasia 3 
by inflammation in the skin tissues (Supplementary Fig. 2). The exact reason for increase of IL-6 4 
mRNA in the group of s.c. injection of etanercept is unclear. However, various inflammatory 5 
cytokines and signal pathways including NF-κB and signal transducer and activator of transcription 6 
(STAT) are intricately involved in pathological progression of psoriasis [33]. The reason that IL-6 7 
mRNA increased about 2-fold is considered that s.c. injection induced production of several 8 
cytokines around the psoriasis sites via needle-induced skin surface bleeding, tissue cut, bruising, 9 
and blood vessel breakage [35]. Then, the inflammatory pathways including NF-κB and STAT were 10 
activated, resulting in increase of downstream IL-6 mRNA expression. The reason why the mRNA 11 
levels of TNF-α and IL-6 tended to be elevated by s.c. injection of etanercept in the non-lesion sites 12 
is also unclear. It has been reported that psoriasis is recognized as a chronic and immune-mediated 13 
disease involved in systemic inflammation [36, 37]. It is presumed that, by needle insertion into the 14 
non-psoriatic lesion site, inflammation reaction was promoted around the injection site, resulting in 15 
increase of the mRNA levels of TNF-α and IL-6 around the non-lesion site. On the other hand, 16 
intradermal administration of etanercept via IP significantly reduced IL-6 mRNA levels without 17 
induction of further inflammation into psoriatic skin. Moreover, etanercept delivered via IP showed 18 
significantly higher therapeutic effect on epidermis hyperplasia induced by psoriasis than s.c. 19 
injected etanercapt (Fig. 7). An advantage of IP over s.c. injection is that s.c.-injected drug solution 20 
rapidly diffuses in skin tissue, whereas IP-administered drugs can permeate evenly into the skin. In 21 
addition, it has also been reported that drugs that permeate into the skin tissue via IP gradually move 22 
into the bloodstream via the skin acting as a drug reservoir [12, 20]. Taken together, these findings 23 
suggest that IP should be useful as a non-invasive and efficient intradermal delivery technology of 24 
biological macromolecular drugs, without causing an inflammatory reaction. 25 
26 
 
 We recently reported that weak electric current treatment for IP can deliver hydrophilic 1 
macromolecules, such as siRNA and antibodies, into the cytoplasm by inducing endocytosis with 2 
unique properties in vitro [38-40]. The resultant endosomes induced by this unique endocytosis 3 
process have been suggested to allow macromolecules (M.W. less than ca. 70,000) to leak through 4 
ceramide pores formed in the endosomal membranes [41]. In the case of cytoplasmic delivery of 5 
antibodies (M.W. 150,000) into cultured cells, we combined weak current treatment with chloroquine, 6 
which is an endosome disrupting agent, to overcome the limitation of high molecular weight 7 
macromolecules not being able to escape from endosomes. In this study, biological macromolecular 8 
drugs were successfully delivered into skin tissue and shown to subsequently capture target 9 
inflammatory cytokines, resulting in psoriasis-induced IL-6 upregulation. It is speculated that some 10 
of the intradermally delivered macromolecular drugs by IP were taken up into the skin cells; 11 
although such molecules likely cannot escape from the endosomes. Thus, by modification of 12 
biological macromolecular drugs with certain elements that promote endosomal escape, it should be 13 
possible to capture intracellular target molecules involved in pathological progression of diseases, as 14 
well as extracellular molecules (e.g., inflammatory cytokines) by using an IP-mediated delivery 15 
system. Design and IP-mediated delivery of such functional macromolecular drugs should be useful 16 
and interesting for future studies. 17 
 In the present study, intradermal delivery of biological macromolecular drugs with retained 18 
functionality was achieved by IP. High costs and frequent administration are generally associated 19 
with treatments that involve biological macromolecular drugs, which proves to be an economic 20 
burden for patients [6]. As shown in Figs. 5 and 6, IP-mediated delivery demonstrated a superior 21 
effect of etanercept on inflammatory signals induced by psoriasis, compared with the effect of s.c. 22 
injection, resulting in significantly higher therapeutic effect on epidermis hyperplasia in the group of 23 
etanercept delivered via IP (Fig. 7). Thus, non-invasive and efficient drug delivery by IP is expected 24 
to improve quality of life for patients. Although we could observe intradermal permeation of 25 
FITC-IgG and therapeutic effect of IP-delivered etanercept in this study, determination of the amount 26 
27 
 
of biological macromolecular drugs in the skin tissues could not be achieved. Hence, establishment 1 
of a method for quantifying the intradermally delivered drugs is important issue in future study. We 2 
also previously succeeded in treating diabetes by IP of insulin-encapsulated liposomes [20], cancer 3 
immunotherapy by IP delivery of antigen-possessing nanogels [21] or CpG-oligo DNA [19], and 4 
suppression of upregulation of specific mRNA in atopic skin [18]. The results of both our past and 5 
present studies suggest that an intradermal drug delivery system using IP offers the potential to be 6 
applied to diverse therapeutic agents for the treatment of various diseases. 7 
 8 
 9 
5. Conclusions 10 
 In summary, the present study demonstrated that non-invasive and efficient intradermal 11 
delivery of antibodies was achieved by IP using weak electric current (0.4 mA/cm2). Transdermally 12 
delivered antibodies extended from the epidermis layer to the dermis layer. We also demonstrated the 13 
successful IP-mediated delivery of antibodies into psoriatic inflamed skin tissue in IMQ-treated 14 
psoriasis model rats. In addition, upregulation of mRNA levels of IL-6, which is involved in 15 
pathological progression of psoriasis, was significantly suppressed by IP of etanercept (anti-TNF-α 16 
drug: recombinant human TNF-α receptor), while levels were not suppressed following s.c. injection. 17 
Importantly, IP administration of etanercept significantly ameliorated epidermis hyperplasia in 18 
IMQ-treated psoriasis model rats, and the effect was significantly higher than s.c. injected etanercept. 19 
Taken together, these results suggest that IP can be applied as a non-invasive and efficient 20 
intradermal drug delivery technology for biological macromolecular drugs, such as antibodies and 21 
anti-cytokine therapeutics. To the best of our knowledge, this is the first report of intradermal 22 
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Figure legends 1 
 2 
Fig. 1. Intradermal distribution of fluorescent-labeled antibody delivered by iontophoresis (IP). 3 
 Confocal images of 10-µm frozen skin sections of hairless rats applied with FITC-IgG 4 
without IP (0.4 mA/cm2) for 3 h (A; n=3) and 3 h after treatment by 1-h IP alone (B; n=3). The 5 
hairless rats were also transdermally administered FITC-IgG via 1-h IP. At 0 h (C; n=4) and 3 h (D 6 
and E; n=4) after 1-h IP, FITC fluorescence was observed by confocal microscopy. Scale bars = 100 7 
µm. Image of dorsal skin tissue of hairless rats stained with HE (F). Stratum corneum, epidermis, and 8 
dermis. Scale bar = 100 µm.  9 
 10 
Fig. 2. Transdermal permeation of fluorescence-labeled antibody via the cleaved intercellular 11 
junctions induced by IP. 12 
 The rats were transdermally administered FITC-IgG via 1-h IP. Three hours after 1-h IP, the 13 
skins of the rats were dissected, and 10-µm frozen sections were prepared, followed by 14 
immunostaining for an intercellular gap junction protein Cx43. The fluorescence images of the skin 15 
were obtained by confocal laser scanning microscopy. The images of the skin sections (A; IP (-)), (B; 16 
IP (+)/FITC-IgG (-), (C) IP (+)/FITC-IgG (+)) are shown. (C) The images in left column indicate the 17 
images obtained around the epidermis and those in right column around the dermis. Green and red 18 
indicate FITC (IgG) and Alexa647 (Cx43), respectively. Merged images of FITC, Alexa647, and 19 
blight field are shown. Scale bars = 50 µm. The experiments were independently performed three 20 
times. 21 
 22 
Fig. 3. Evaluation of psoriatic skin inflammation in IMQ-induced psoriasis model rats. 23 
 The psoriasis model rats were prepared by topical application of IMQ cream (60 24 
mg/rat/treatment) a total of four times. Eight days after the 1st IMQ treatment (day 1), 10-µm frozen 25 
skin sections were prepared, and HE staining was performed. Microscopic images of skin sections 26 
34 
 
from normal (A) and IMQ-treated psoriasis model rats (B). Scale bars = 100 µm.  1 
 2 
Fig. 4. Iontophoretic delivery of fluorescent-labeled antibody into the dorsal skin of IMQ-induced 3 
psoriasis model rats. 4 
 Experimental schedule (A). Twenty-four hours (day 5) after the 4th IMQ treatment (day 4), 5 
the rats were treated with FITC-IgG alone (B; n=3), IP alone (C; n=3), or IP administration of 6 
FITC-IgG (D; n=3), followed by preparation of 10-µm frozen skin sections 3 h after treatment. In 7 
those rats administered FITC-IgG by IP twice (E; n=3, day 5 and 7), the sections were prepared 3 h 8 
after the 2nd treatment. Confocal images of each group are shown (B; IP (-)/FITC-IgG (+), C; IP 9 
(+)/FITC-IgG (-), D; IP (+)/FITC-IgG (+) 1 time, E; IP (+)/FITC-IgG (+) 2 times). Merged images of 10 
phase contrast, DAPI (nuclei; blue), and FITC (IgG; green) are shown. Scale bars = 100 µm. 11 
 12 
Fig. 5. Effects of IP-mediated etanercept treatment on inflammatory cytokine mRNA levels in 13 
psoriasis model rats. 14 
 IMQ-treated psoriasis model rats were transdermally administered etanercept (1 mg 15 
dose/rat) or PBS via IP 5 and 7 days after the start of IMQ treatment (A). Eight days after the start of 16 
IMQ treatment, the mRNA levels of TNF-α (B) and IL-6 (C) were assessed. The relative transcript 17 
levels of TNF-α and IL-6 in IMQ (+) to those in the IMQ (-) non-treated group are presented. In the 18 
IP-treated group, the mRNA levels of TNF-α (D) and IL-6 (E) were assessed at 24 h after the 2nd IP 19 
treatment. The relative transcript levels in each group to those in the IMQ (+) non-treated group are 20 
presented. Data are mean ± S.D. (n=4). ** P<0.01, *** P<0.001. 21 
 22 
Fig. 6. Effects of subcutaneous (s.c.) injection of etanercept on inflammatory cytokine mRNA levels 23 
in the psoriasis model rats. 24 
 IMQ-treated psoriasis model rats were subcutaneously injected with etanercept (1 mg 25 
dose/rat) or PBS at 5 and 7 days after the start of IMQ treatment (A). In etanercept-treated groups, s.c. 26 
35 
 
injections were performed directly into the psoriatic inflammatory skin (lesion site) or the distal area 1 
from the diseased site (non-lesion site), respectively. Twenty-four hours after the 2nd s.c. injection, 2 
the mRNA levels of TNF-α (B) and IL-6 (C) were evaluated. The relative transcript levels of TNF-α 3 
and IL-6 in each group to those in the IMQ (+) group are presented. Data are mean ± S.D. (n=3). * 4 
P<0.05. 5 
 6 
Fig. 7. Amelioration of epidermis hyperplasia by etanercept delivered via IP in psoriasis model rats. 7 
 Etanercept (1 mg dose/rat) was transdermally (IP) or subcutaneously administered 5 and 7 8 
days after the start of IMQ treatment. Eight days after the start of IMQ treatment, the 10-µm frozen 9 
skin sections were prepared and stained with HE. Microscopic images of skin sections from normal 10 
(A; n=3), IMQ-treated psoriasis model rats (B; n=4), the model rats treated with etanercept 11 
administered by IP (C; n=4) or s.c. injection (D; n=4). Scale bars = 100 µm. From the images of 12 
HE-stained skin sections, epidermis thickness of each group of rats was measured (E). Data are mean 13 





Table 1. Primer sequences for real-time RT-PCR. 1 
   
Gene Forward Reverse 
GAPDH CCCCCAATGTATCCGTTGTG TAGCCCAGGATGCCCTTTAGT 
TNF-α CGTAGCAAACCACCAAGCA CGTAGCAAACCACCAAGCA 
IL-6 TCCTACCCCAACTTCCAATGCTC TTGGATGGTCTTGGTCCTTAGCC 
      
 2 
